Key points from article :
Biolexis Therapeutics, an AI-driven drug discovery company, raised $10 million to develop metabolic drugs.
Their drug candidates target obesity, diabetes, and potentially, human longevity.
Biolexis uses its AI platform, MolecuLern, to rapidly identify and develop drug candidates.
The company has 40 active discovery programs and 10 IND-enabling programs, focusing on metabolic disorders.
Biolexis launched Metabolexis, a subsidiary focused on oral drugs for obesity, diabetes, and longevity.
Metabolexis plans to file INDs for 3 agents by 2024 and initiate Phase I trials in early 2025.
